Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study... od Milojkovic, D, Cross, NCP, Ali, S, Mead, A, Et al.

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK od Cross, N, White, H, Evans, P, Hancock, J, Copland, M, Milojkovic, D, Mason, J, Craine, S, Mead, A

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis od Psaila, B, Heuston, E, Milojkovic, D, Lichtenberg, J, Anderson, S, Hoffman, R, Roberts, I, Mead, A, Bodine, D, Barkas, N, Progra, N

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. od Chaidos, A, Patterson, S, Szydlo, R, Chaudhry, M, Dazzi, F, Kanfer, E, McDonald, D, Marin, D, Milojkovic, D, Pavlu, J, Davis, J, Rahemtulla, A, Rezvani, K, Goldman, J, Roberts, I, Apperley, J, Karadimitris, A

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study od Harrison, C, Mendez-Ferrer, S, Houlton, A, Sirovica, M, Drummond, M, McMullin, M, Mead, A, Milojkovic, D, Ewing, J, Cargo, C, Butt, N, Wadelin, F, Chen, F, Coppell, J, Francis, S, Narayanan, S, Knapper, S, Godfrey, A

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. od Innes, A, Beattie, R, Sergeant, R, Damaj, D, Foroni, L, Marin, D, Kanfer, E, Mielke, S, Milojkovic, D, MacDonald, D, Pavlu, J, Rahemtulla, A, Roberts, I, Slade, D, Bray, E, Goldman, J, Apperley, J, Szydlo, R, Dazzi, F, Rezvani, K

Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets od Psaila, B, Wang, G, Rodriguez-Meira, A, Li, R, Heuston, EF, Murphy, L, Yee, D, Hitchcock, IS, Sousos, N, O'Sullivan, J, Anderson, S, Senis, YA, Weinberg, OK, Calicchio, ML, NIH Intramural Sequencing Center, Iskander, D, Royston, D, Milojkovic, D, Roberts, I, Bodine, DM, Thongjuea, S, Mead, AJ

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm od Salisbury, RA, Curto-Garcia, N, O'Sullivan, J, Chen, F, Polzella, P, Godfrey, AL, Russell, J, Knapper, S, Willan, J, Frewin, R, Joshi, S, Arami, S, Burns, S, Teh, CH, Wadelin, F, Dhanapal, J, Neelakantan, P, Milojkovic, D, Psaila, B, Szydlo, R, Francis, S, Cargo, C, Jain, M, McGregor, A, Wallis, L, Duncombe, A, Hussein, H, Dyer, P, Munro, L, Bond, L, McMullin, MF, Somervaille, TCP, Garg, M, Sekhar, M, Harrison, C, Mead, AJ, Innes, AJ

Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis od Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S